Ralph H. Johnson VA Medical Center

As an affiliate of the Medical University of South Carolina, Ralph H. Johnson VA Medical Center is an active NCORP site. Ralph H. Johnson VA Medical Center is currently active on multiple clinical trials addressing various cancer types. Ask your health care provider for more information.

Bone Marrow Transplant

• S1803: Testing the addition of a new drug, daratumumab/rHuPH20, to the usual treatment (lenalidomide) as post-stem cell transplant treatment for multiple myeloma.
  This phase III trial compares the effect of usual treatment (lenalidomide) to using daratumumab/rHuPH20 plus the usual treatment after stem cell transplantation in patients with multiple myeloma.

Gastrointestinal

• A021806: Testing the use of the usual chemotherapy before and after surgery for removable pancreatic cancer.
  This trials compares perioperative chemotherapy (given around the time of surgery) to adjuvant chemotherapy (given after surgery) for treatment of pancreatic cancer that can be removed by surgery.
• CC005: A study to examine how often (every 5 years or 10 years) a colonoscopy should be done in participants who had one or two small growths of tissue removed from their colon.
  This trial compares how often (every 5 of 10 years versus every 10 years) a colonoscopy should be done in participants who had one or two non-cancerous polyps removed from their colon.
• S2303: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
  To compare progression-free survival between those randomized to nivolumab + paclitaxel + ramucirumab versus those randomized to paclitaxel + ramucirumab.EA8212 - To determine the event free survival and quality of life of BCG-naïve high grade non-muscle invasive bladder cancer patients treated with intravesical BCG vs GEMDOCE.

Genitourinary

• A031803: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer.
  This trial studies the effect of adding the immunotherapy drug pembrolizumab to gemcitabine for patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment.
• EA8184: To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring (Pending Activation).
  This trial studies whether green tea catechins can prevent progression of prostate cancer from a low-risk stage to a higher-risk stage in men on active surveillance.
• EA8212: A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
  To determine the event free survival and quality of life of BCG-naïve high grade non-muscle invasive bladder cancer patients treated with intravesical BCG vs GEMDOCE.
• S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
  To study how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Malignant Hematology

• S1925: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
  To compare early vs. delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Thoracic/Lung

• EA5221: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
  To evaluate whether there is an improvement in overall survival (OS) with chemotherapy combined with pembrolizumab compared to single agent pembrolizumab in this vulnerable older adult patient population.
• LungMAP: Targeted Treatment for Advanced Non-Small Cell Lung Cancer.
  This trial will test patient specimens to determine eligibility in biomarker-driven and non-matched substudies included within the LungMAP umbrella protocol.